Bajaj HealthCare
BAJAJHCARE NSE
Bajaj HealthCare
HealthcareNSE: BAJAJHCARE BSE: 539872 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹1,121 Cr
Volatility
Moderate
P/E Ratio
57.99
EBITDA
₹112 Cr
Return on Equity
4%
Debt to Equity
0.47
Book Value
₹158.34
EPS
₹10.38
52W High
₹515.9
52W Low
₹272.35
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
5- The company has delivered a poor sales growth of -1.44% over past five years.
- Company has a low return on equity of 3.48% over last 3 years.
- Dividend payout has been low at 12.2% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -8.90%
- Working capital days have increased from 90.8 days to 132 days
Growth Rate
Revenue Growth
10% higher than
3Y
Net Income Growth
-50.35% lower than
3Y
Cash Flow Change
169% higher than
3Y
ROE
-56.57% lower than
3Y
ROCE
-36.72% lower than
3Y
EBITDA Margin (Avg.)
-0.06% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 130 | 101 | 109 | 134 | 132 | 133 | 123 | 154 | 149 | 148 | 161 | 153 | 166 |
| Expenses | 108 | 82 | 89 | 118 | 108 | 109 | 101 | 143 | 124 | 121 | 131 | 130 | 137 |
| Operating Profit | 22 | 19 | 20 | 16 | 24 | 25 | 22 | 12 | 25 | 27 | 31 | 23 | 29 |
| OPM % | 17% | 19% | 18% | 12% | 19% | 18% | 18% | 8% | 16% | 18% | 19% | 15% | 17% |
| Other Income | -55 | -7 | -7 | -36 | 0 | 4 | -1 | 13 | 1 | 0 | 1 | -34 | 1 |
| Interest | 9 | 8 | 7 | 6 | 8 | 8 | 6 | 6 | 5 | 6 | 6 | 6 | 6 |
| Depreciation | 6 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 6 | 7 | 7 | 8 | 7 |
| PBT | -48 | -3 | -1 | -33 | 9 | 14 | 8 | 11 | 14 | 15 | 19 | -24 | 16 |
| Tax % | 0% | 4% | 58% | -10% | 23% | 30% | -39% | 1% | 17% | 24% | 17% | -6% | 16% |
| Net Profit | -48 | -3 | -2 | -30 | 7 | 9 | 12 | 11 | 12 | 11 | 16 | -23 | 14 |
| EPS in Rs | -17.47 | -1.25 | -0.8 | -10.84 | 2.58 | 3 | 3.71 | 3.54 | 3.75 | 3.52 | 4.96 | -6.79 | 4.07 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 646 | 473 | 543 | 611 | 628 |
| Expenses | 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 534 | 397 | 460 | 506 | 519 |
| Operating Profit | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 112 | 76 | 83 | 105 | 109 |
| OPM % | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 17% | 16% | 15% | 17% | 17% |
| Other Income | 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | -19 | -105 | 16 | -32 | -32 |
| Interest | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 18 | 30 | 28 | 22 | 23 |
| Depreciation | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 17 | 28 | 28 | 28 | 29 |
| PBT | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -86 | 43 | 23 | 25 |
| Tax % | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 25% | -3% | 7% | 33% | — |
| Net Profit | 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -84 | 40 | 16 | 18 |
| EPS in Rs | 8.34 | 3.04 | 2.83 | 5.5 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -30.36 | 12.51 | 4.68 | 5.76 |
| Div. Payout % | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% | -3% | 8% | 32% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 | 16 | 17 |
| Reserves | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 265 | 450 | 516 |
| Borrowings | 70 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 333 | 223 | 249 |
| Other Liabilities | 38 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 115 | 154 | 144 | 141 |
| Total Liabilities | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 | 923 |
| Fixed Assets | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 253 | 238 | 248 |
| CWIP | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 7 | 3 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 510 | 506 | 591 | 667 |
| Total Assets | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 | 923 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | 92 | 22 | 58 |
| Investing | -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | -11 | -15 | -48 |
| Financing | -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 131 | -97 | -6 | 24 |
| Net Cash Flow | 0 | 0 | 0 | 7 | 0 | -4 | 10 | -12 | 16 | -16 | 0 | 35 |
| Free Cash Flow | 11 | -6 | 14 | 5 | 11 | -2 | -70 | -74 | -115 | 73 | 10 | 18 |
| CFO/OP | 99 | 100 | 88 | 57 | 89 | 62 | 58 | 9 | -10 | 138 | 32 | 53 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 110 | 139 | 169 | 140 |
| Inventory Days | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 199 | 206 | 206 | 249 |
| Days Payable | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 81 | 128 | 127 | 133 |
| Cash Conversion Cycle | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 228 | 217 | 248 | 256 |
| Working Capital Days | -11 | -17 | -4 | 0 | 12 | 24 | 34 | 40 | 27 | 0 | 141 | 132 |
| ROCE % | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 14% | 8% | 11% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bajaj HealthCare insights
68 extracted metrics + investor summaries across FY11–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Dividend Updates
1d - Board approved FY26 audited results, recommended Rs1.50 final dividend, and appointed internal and cost auditors. 1d - Board approved FY26 audited results, recommended Rs1.50 final dividend, and appointed internal and cost auditors.
2
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
8 May - Board approved FY26 audited results, recommended Rs1.50 final dividend, and appointed internal and cost auditors. 8 May - Board approved FY26 audited results, recommended Rs1.50 final dividend, and appointed internal and cost auditors.
3
Announcement under Regulation 30 (LODR)-Press Release / Media Release
8 May - Bajaj Healthcare reported Q4 FY26 results, FY26 revenue up 12.6%, and converted 2,079,409 warrants for ₹527 million. 8 May - Bajaj Healthcare reported Q4 FY26 results, FY26 revenue up 12.6%, and converted 2,079,409 warrants for ₹527 million.
4
Compliances-Statement Of Deviation & Variation
8 May - Quarter ended 31 March 2026 statement confirms no deviation in preferential issue proceeds. 8 May - Quarter ended 31 March 2026 statement confirms no deviation in preferential issue proceeds.
5
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
8 May - CARE report for quarter ended March 31, 2026 shows Rs 204.97 crore preferential issue utilization with no deviation. 8 May - CARE report for quarter ended March 31, 2026 shows Rs 204.97 crore preferential issue utilization with no deviation.
Frequently Asked Questions about Bajaj HealthCare
What does Bajaj Healthcare Ltd do?
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
Where is Bajaj Healthcare Ltd (BAJAJHCARE) listed?
Bajaj Healthcare Ltd trades as BAJAJHCARE on the NSE and under code 539872 on the BSE.
Which sector does Bajaj Healthcare Ltd belong to?
Bajaj Healthcare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bajaj Healthcare Ltd?
Bajaj Healthcare Ltd has a market capitalisation of ₹1,121 Cr, which places it in the Small Cap band.
What is the PE ratio of Bajaj Healthcare Ltd?
Bajaj Healthcare Ltd trades at a PE ratio of 57.99, on earnings per share of ₹10.38, against a book value of ₹158.34 per share.
What is the 52-week high and low of Bajaj Healthcare Ltd?
Over the last 52 weeks Bajaj Healthcare Ltd has traded between ₹272.35 and ₹515.9.
Does Bajaj Healthcare Ltd pay dividends?
Bajaj Healthcare Ltd has a dividend yield of 0.45%.
What is the Return on Equity (ROE) of Bajaj Healthcare Ltd?
Bajaj Healthcare Ltd reported a return on equity of 4.00%. Its debt-to-equity ratio is 0.47.
Company Information
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
Website bajajhealth.com
CEO Mr. Sajankumar Rameshwarlal Bajaj
Employees 918
Listed 2021-11-25
Face Value ₹ 5
Issued Size 3,15,83,252
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BAJAJHCARE.md for Bajaj Healthcare Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.